Exploring Non-Insulin Therapies for Type 2 Diabetes

This chapter delves into the evolving landscape of non-insulin therapies for type 2 diabetes, emphasizing the importance of Metformin as a first-line treatment and discussing newer options like GLP1 receptor agonists and SGLT2 inhibitors, highlighting their benefits and considerations for different patient profiles. It also touches on various oral agents for diabetes and includes insights from a study on the effectiveness of a high-dose recombinant influenza vaccine compared to a standard dose vaccine.